
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
The FDA has approved Cubicin, a product of Cubist Pharmaceuticals that was formally called Cidecin, for treatment of complicated skin and structure infections caused by gram-positive bacteria.